Shots:

• The companies collaborated to commercialize Bioeq's FYB201 (biosimilar referencing Lucentis) in the EU- Canada- Israel & New Zealand
• Bioeq will be responsible for the development- registration- and supply of the biosimilar while Teva will be responsible for commercializing the product. The companies will share revenue from the commercialization of the biosimilar
• The collaboration will expand Teva’s biosimilar portfolio & strengthen the development of biosimilar drugs for highly regulated countries. Additionally- Bioeq has in licensed the exclusive global commercialization rights to FYB201 from Formycon

  | Ref: Teva | Image: Rasayanika